



KAREN L. SMITH, MD, MPH  
Director & State Health Officer

State of California—Health and Human Services Agency  
California Department of Public Health



GAVIN NEWSOM  
Governor

Office of AIDS (OA)  
AIDS Drug Assistance Program (ADAP)

Management Memorandum  
Memorandum Number: 2019-08

DATE: March 19, 2019

TO: ADAP ENROLLMENT WORKERS

SUBJECT: **ADDITION OF LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE (CIMDUO™) AND EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE (SYMFI™) TO THE ADAP FORMULARY**

**Effective March 8, 2019**, lamivudine/tenofovir disoproxil fumarate (Cimduo™) and efavirenz/lamivudine/tenofovir disoproxil fumarate (Symfi™) have been added to the ADAP formulary.

Cimduo™, a two-drug combination of lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg, both nucleoside analog reverse transcriptase inhibitors, received Food and Drug Administration (FDA) approval on February 28, 2018. Cimduo™ was approved as a once-daily single-tablet combination regimen for the treatment of HIV-1 infection. The ADAP Medical Advisory Committee (MAC) voted for the addition of Cimduo™ to the ADAP formulary.

Symfi™, a three-drug combination of efavirenz 600 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg, received FDA approval on March 28, 2018, as a once-daily complete single-tablet regimen for the treatment of HIV-1 infection. The ADAP MAC voted on the addition Symfi™ to the ADAP formulary.

Although these combination drugs were approved by the FDA in February and March of 2018 respectively, the manufacturer of Cimduo™ and Symfi™ announced that the medications would not be available until the second quarter of 2018. Due to the delayed release date, ADAP was unable to determine finalized pricing until mid-February of 2019.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The [ADAP drug formulary](https://cdph.magellanrx.com/member/documents) has been updated to reflect the addition of Cimduo™ and Symfi™; it can be accessed at the following url: (<https://cdph.magellanrx.com/member/documents>).

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Thank you,

A handwritten signature in blue ink, appearing to read 'Sandra Robinson', with a stylized flourish at the end.

Sandra Robinson, MBA  
ADAP Branch Chief  
California Department of Public Health